Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ингибиторы дипептидилпептидазы-4 при лечении сахарного диабета типа 2
Ингибиторы дипептидилпептидазы-4 при лечении сахарного диабета типа 2
Моргунова Т.Б., Фадеев В.В. Ингибиторы дипептидилпептидазы-4 при лечении сахарного диабета типа 2. Consilium Medcium. 2016; 18 (4): 20–23. DOI: 10.26442/2075-1753_2016.4.20-23
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Сахарный диабет типа 2 – одно из наиболее часто встречающихся эндокринных заболеваний. В статье обсуждаются новые классы сахароснижающих препаратов (ингибиторы дипептидилпептидазы-4, агонисты рецепторов глюкагоноподобного пептида-1, ингибиторы натрий-глюкозного котранспортера-2), подходы к их назначению. Также рассматриваются вопросы кардиоваскулярной безопасности современных сахароснижающих препаратов.
Ключевые слова: сахарный диабет 2 типа, сахароcнижающие препараты, лечение, ингибиторы дипептидилпептидазы-4.
Key words: type 2 diabetes mellitus, antihyperglycemic agents, dipeptidyl peptidase 4 inhibitors.
Ключевые слова: сахарный диабет 2 типа, сахароcнижающие препараты, лечение, ингибиторы дипептидилпептидазы-4.
________________________________________________
Key words: type 2 diabetes mellitus, antihyperglycemic agents, dipeptidyl peptidase 4 inhibitors.
Полный текст
Список литературы
1. Godinho R, Mega C, Teixeira-de-Lemos E et al. The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? J Diabetes Res 2015; 2015: 806979. Doi: 10.1155/2015/806979. Epub 2015 May 17. Review.
2. Дедов И.И., Шестакова М.В., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой (7-й выпуск). Сахарный диабет. 2015; 18 (1S): 1–112. / Dedov I.I., Shestakova M.V., Galstjan G.R. i dr. Algoritmy specializirovannoj medicinskoj pomoshhi bol'nym saharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoj (7-j vypusk). Saharnyj diabet. 2015; 18 (1S): 1–112. [in Russian]
3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–79.
4. Seino Y, Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Exp Opin Pharmacother 2014; 15 (6): 851–63. Doi: 10.1517/14656566.2014.898750.
5. Christopher R, Covington P, Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidylpeptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008; 30: 513–27.
6. Pratley RE, Kipnes MS, Fleck PR et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11: 167–76.
7. Pratley RE, Reusch JE, Fleck PR et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled study. Curr Med Res Opin 2009; 25: 2361–71.
8. Rosenstock J, Rendell MS, Gross JL et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009; 11: 1145–52.
9. Nauck MA, Ellis GC, Fleck PR et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009; 63: 46–55.
10. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared to glipizide over 2 years when used in combination with metformin. Diabetes Obes Metab 2014; 16 (12): 1239–46. Doi: 10.1111/dom.12377. Epub 2014 Sep 25.
11. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31: 2315–7.
12. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2010; 321: 405–12.
13. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–53.
14. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.
15. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355 (23): 2427–43.
16. Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64 (5): 562–76. Doi: 10.1111/j.1742-241.2010.02353.x.
17. Göke R, Bader G, Dworak M. Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany. Diabetes Ther 2014; 5 (1): 183–91. Doi: 10.1007/s13300-014-0060-4. Epub 2014 Mar 19.
18. Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012; 380 (9840): 475–83. Doi: 10.1016/S0140-6736(12)60691-6. Epub 2012 Jun 28.
19. Matthews DR, Dejager S, Ahren B et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12 (9): 780–9. Doi: 10.1111/j.1463-1326.2010.01233.x.
20. Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2015; 109 (2): 378–88. Doi: 10.1016/j.diabres.2015.05.025. Epub 2015 May 14. Review.
21. FDA Guidance for Industry. Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
22. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–35.
2. Dedov I.I., Shestakova M.V., Galstjan G.R. i dr. Algoritmy specializirovannoj medicinskoj pomoshhi bol'nym saharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoj (7-j vypusk). Saharnyj diabet. 2015; 18 (1S): 1–112. [in Russian]
3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–79.
4. Seino Y, Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Exp Opin Pharmacother 2014; 15 (6): 851–63. Doi: 10.1517/14656566.2014.898750.
5. Christopher R, Covington P, Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidylpeptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008; 30: 513–27.
6. Pratley RE, Kipnes MS, Fleck PR et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11: 167–76.
7. Pratley RE, Reusch JE, Fleck PR et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled study. Curr Med Res Opin 2009; 25: 2361–71.
8. Rosenstock J, Rendell MS, Gross JL et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009; 11: 1145–52.
9. Nauck MA, Ellis GC, Fleck PR et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009; 63: 46–55.
10. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared to glipizide over 2 years when used in combination with metformin. Diabetes Obes Metab 2014; 16 (12): 1239–46. Doi: 10.1111/dom.12377. Epub 2014 Sep 25.
11. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31: 2315–7.
12. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2010; 321: 405–12.
13. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–53.
14. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.
15. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355 (23): 2427–43.
16. Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64 (5): 562–76. Doi: 10.1111/j.1742-241.2010.02353.x.
17. Göke R, Bader G, Dworak M. Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany. Diabetes Ther 2014; 5 (1): 183–91. Doi: 10.1007/s13300-014-0060-4. Epub 2014 Mar 19.
18. Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012; 380 (9840): 475–83. Doi: 10.1016/S0140-6736(12)60691-6. Epub 2012 Jun 28.
19. Matthews DR, Dejager S, Ahren B et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12 (9): 780–9. Doi: 10.1111/j.1463-1326.2010.01233.x.
20. Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2015; 109 (2): 378–88. Doi: 10.1016/j.diabres.2015.05.025. Epub 2015 May 14. Review.
21. FDA Guidance for Industry. Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
22. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–35.
2. Дедов И.И., Шестакова М.В., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой (7-й выпуск). Сахарный диабет. 2015; 18 (1S): 1–112. / Dedov I.I., Shestakova M.V., Galstjan G.R. i dr. Algoritmy specializirovannoj medicinskoj pomoshhi bol'nym saharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoj (7-j vypusk). Saharnyj diabet. 2015; 18 (1S): 1–112. [in Russian]
3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–79.
4. Seino Y, Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Exp Opin Pharmacother 2014; 15 (6): 851–63. Doi: 10.1517/14656566.2014.898750.
5. Christopher R, Covington P, Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidylpeptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008; 30: 513–27.
6. Pratley RE, Kipnes MS, Fleck PR et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11: 167–76.
7. Pratley RE, Reusch JE, Fleck PR et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled study. Curr Med Res Opin 2009; 25: 2361–71.
8. Rosenstock J, Rendell MS, Gross JL et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009; 11: 1145–52.
9. Nauck MA, Ellis GC, Fleck PR et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009; 63: 46–55.
10. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared to glipizide over 2 years when used in combination with metformin. Diabetes Obes Metab 2014; 16 (12): 1239–46. Doi: 10.1111/dom.12377. Epub 2014 Sep 25.
11. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31: 2315–7.
12. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2010; 321: 405–12.
13. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–53.
14. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.
15. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355 (23): 2427–43.
16. Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64 (5): 562–76. Doi: 10.1111/j.1742-241.2010.02353.x.
17. Göke R, Bader G, Dworak M. Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany. Diabetes Ther 2014; 5 (1): 183–91. Doi: 10.1007/s13300-014-0060-4. Epub 2014 Mar 19.
18. Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012; 380 (9840): 475–83. Doi: 10.1016/S0140-6736(12)60691-6. Epub 2012 Jun 28.
19. Matthews DR, Dejager S, Ahren B et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12 (9): 780–9. Doi: 10.1111/j.1463-1326.2010.01233.x.
20. Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2015; 109 (2): 378–88. Doi: 10.1016/j.diabres.2015.05.025. Epub 2015 May 14. Review.
21. FDA Guidance for Industry. Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
22. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–35.
________________________________________________
2. Dedov I.I., Shestakova M.V., Galstjan G.R. i dr. Algoritmy specializirovannoj medicinskoj pomoshhi bol'nym saharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoj (7-j vypusk). Saharnyj diabet. 2015; 18 (1S): 1–112. [in Russian]
3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–79.
4. Seino Y, Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Exp Opin Pharmacother 2014; 15 (6): 851–63. Doi: 10.1517/14656566.2014.898750.
5. Christopher R, Covington P, Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidylpeptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008; 30: 513–27.
6. Pratley RE, Kipnes MS, Fleck PR et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11: 167–76.
7. Pratley RE, Reusch JE, Fleck PR et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled study. Curr Med Res Opin 2009; 25: 2361–71.
8. Rosenstock J, Rendell MS, Gross JL et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009; 11: 1145–52.
9. Nauck MA, Ellis GC, Fleck PR et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009; 63: 46–55.
10. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared to glipizide over 2 years when used in combination with metformin. Diabetes Obes Metab 2014; 16 (12): 1239–46. Doi: 10.1111/dom.12377. Epub 2014 Sep 25.
11. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31: 2315–7.
12. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2010; 321: 405–12.
13. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–53.
14. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.
15. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355 (23): 2427–43.
16. Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64 (5): 562–76. Doi: 10.1111/j.1742-241.2010.02353.x.
17. Göke R, Bader G, Dworak M. Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany. Diabetes Ther 2014; 5 (1): 183–91. Doi: 10.1007/s13300-014-0060-4. Epub 2014 Mar 19.
18. Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012; 380 (9840): 475–83. Doi: 10.1016/S0140-6736(12)60691-6. Epub 2012 Jun 28.
19. Matthews DR, Dejager S, Ahren B et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12 (9): 780–9. Doi: 10.1111/j.1463-1326.2010.01233.x.
20. Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2015; 109 (2): 378–88. Doi: 10.1016/j.diabres.2015.05.025. Epub 2015 May 14. Review.
21. FDA Guidance for Industry. Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
22. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–35.
Авторы
Т.Б.Моргунова*, В.В.Фадеев
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*tanmorgun@mail.ru
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*tanmorgun@mail.ru
________________________________________________
T.B.Morgunova*, V.V.Fadeev
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*tanmorgun@mail.ru
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*tanmorgun@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.